Skip to contentB
Boston Scientific Corp
B
BSXBoston Scientific Corp Q4 2020 · 10-K
derived · Computed from the longer spans the company filed.
Revenue$2.71B$2.71Bderived−6.7% vs Q4 2019 Net Income$209.00M$209.00Mderived−94.8% vs Q4 2019 EPS, diluted—
The same fiscal quarter, prior years. Thaler holds no estimates to compare against.
Boston Scientific Corp · CIK 885725 · Engraved from SEC EDGAR
Not derived. Share counts vary by quarter.
Gross Profitderived$1,709,000,000−16.8% Operating Incomederived$50,000,000−76.2% Operating Cash Flowderived$673,000,000−2.7% Free Cash Flowderived$514,000,000+1.6% Margins · derivedGross margin63.1%−7.6 pt vs Q4 2019
Operating margin1.8%−5.4 pt vs Q4 2019
Net margin7.7%
ended Dec 31, 2020 · filed Feb 23, 2021 · 54 d after period end